This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroToday Home
Conference Highlights
EAU 2025
EAU 2025
Prostate Cancer
Bladder Cancer
Kidney Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Upper Tract Urothelial Carcinoma
Press Releases
EAU 2025 Prostate Cancer
Viewing 1-20 of 34 articles
EAU 2025: Matching-Adjusted Indirect Comparison between Enzalutamide and Darolutamide Doublet Therapy for mHSPC
EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: Evidence for and Against a Second Taxane
EAU 2025: A Case of Progression after Triplet Therapy for mHSPC: PARP Inhibitors Alone or in Combination?
EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: LuPSMA, Who and When?
EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: Evidence for and Against a Second ARPI
EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: Aggressive Variants
EAU 2025: Discussant: PSA Response with Darolutamide plus ADT in Patients with mHSPC in ARANOTE
EAU 2025: Management of Locally Advanced Prostate Cancer: What Is the Standard of Care in 2025? Intensified Approaches with Radiation Therapy
EAU 2025: My Algorithm for Decision Making in mCRPC
EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: Radium-223 Alone or in Combination
EAU 2025: Prehabilitation: Diet, Sleep and Psychological Preparation
EAU 2025: Prehabilitation: The Impact of Exercise, Personalized Programs, and Digital Devices
EAU 2025: PSA Response with Darolutamide plus ADT in Patients with mHSPC in ARANOTE
EAU 2025: High-Risk Biochemical Recurrence with Positive PSMA PET: Radiotherapy Still Matters
EAU 2025: A Phase I/II Study of Neoadjuvant, Intra-Arterial Administration of (177Lu) Lutetium Vipivotid Tetraxetan in Subjects with High-Risk, Localised or Locally Advanced Prostate Cancer (LUPUS)
EAU 2025: Impact of Baseline PSA on Clinical Outcomes in Patients with mHSPC Treated with Darolutamide Triplet Therapy in ARASENS
EAU 2025: Sub-Group Analysis from EORTC-GUCG 1333/PEACE-3, an EORTC/CTI/CUO
EAU 2025: Metastatic Hormone Sensitive Prostate Cancer with a Deep Response to ADT plus ARPI: The Pros and Cons of De-escalation of Systemic Therapy
EAU 2025: Patient with High-risk Localised Prostate Cancer - cT3bN0M0 ISUP Grade Group 5: The Urologist, Radiation Oncologist, and Medical Oncologist Perspectives
EAU 2025: Debate De Novo Low-Volume Metastatic Hormone-Sensitive Prostate Cancer: ADT + ARPI Does It All
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
